The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis
Open accessAbstract
BACKGROUND: Hepatocellular carcinoma (HCC) is a major cause of death in cirrhotic patients. This neoplasm is associated with liver cirrhosis (LC) in more than 90% of cases. Early diagnosis and treatment of HCC are expected to improve survival of patients. AIMS: To assess the cost effectiveness of a surveillance programme of patients with LC for the early diagnosis and treatment of HCC. PATIENTS: A cohort of 313 Italian patients with LC were enrolled in the surveillance programme between March 1989 and November 1991. In the same period, 104 consecutive patients with incidentally detected HCC were referred to our centre and served as a control group. METHODS: Surveillance was based on ultrasonography (US) and α fetoprotein (AFP) determinations repeated at six month intervals. Risk factors for HCC were assessed by multivariate analysis (Cox model). Outcome measures analysed were: (1) number and size of tumours; (2) eligibility for treatment; and (3) survival of patients. Economic issues were: (1) overall cost of surveillance programme; (2) cost per treatable HCC; and (3) cost per year of life saved (if any). Costs were assessed according to charges for procedures at our university hospital. RESULTS: Surveillance lasted a mean of 56 (31) months (range 6–100). During the follow up, 61 patients (19.5%) developed HCC (unifocal at US in 49 cases), with an incidence of 4.1% per year of follow up. AFP, Child-Pugh classes B and C, and male sex were detected as independent risk factors for developing HCC. Only 42 (68.9%) of 61 liver tumours were treated by surgical resection, orthotopic liver transplantation, or local therapy. The cumulative survival rate of the 61 patients with liver tumours detected in the surveillance programme was significantly longer than that of controls (p=0.02) and multivariate analysis showed an association between surveillance and survival. The overall cost of the surveillance programme was US$753 226, the cost per treatable HCC was US$17 934, and the cost for year of life saved was US$112 993. CONCLUSION: Our surveillance policy of patients with LC requires a large number of resources and offers little benefit in terms of patient survival. The decision whether to adopt a surveillance policy towards HCC should rely on the prevalence of the disease in the population and on the resources of a particular country.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Maximum utilization of the life table method in analyzing survival
Cutler, S. J., & Ederer, F. (1958) · Journal of Chronic Diseases · doi:10.1016/0021-9681(58)90126-7 · Cited by 2,870 · cited 1×
“The cumulative rate of HCC detected during the surveillance programme and survival curves for HCC detected during follow up and those in the unsurveilled population were calculated by life tables according to the Kaplan-Maier method”
MethodOkuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., Nakajima, Y., & Ohnishi, K. (1985) · Cancer · doi:10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e · Cited by 1,931
Llovet, J. M., Bustamante, J., Castells, A., Vilana, R., Del Carmen Ayuso, M., Sala, M., Brú, C., Rodés, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510290145 · Cited by 1,190
Recommendations for Reporting Cost-effectiveness Analyses
Siegel, J. E. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540160061034 · Cited by 1,147
Terminology of nodular hepatocellular lesions
Wanless, I. R. (1995) · Hepatology · doi:10.1002/hep.1840220341 · Cited by 1,130
Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver Disease
Tsukuma, H., Hiyama, T., Tanaka, S., Nakao, M., Yabuuchi, T., Kitamura, T., Nakanishi, K., Fujimoto, I., Inoue, A., Yamazaki, H., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282501 · Cited by 1,126
The Distinction Between Cost and Charges
FINKLER, S. A. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-1-102 · Cited by 1,052
Siegel, J. E. (1996) · JAMA · doi:10.1001/jama.276.16.1339 · Cited by 1,037
Hepatocellular Carcinoma in Italian Patients with Cirrhosis
Colombo, M., de Franchis, R., Del Ninno, E., Sangiovanni, A., De Fazio, C., Tommasini, M., Donato, M. F., Piva, A., Di Carlo, V., & Dioguardi, N. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109053251002 · Cited by 813
A Clinician's Guide to Cost-Effectiveness Analysis
Detsky, A. S., & Naglie, I. G. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-2-147 · Cited by 708
Ikeda, K. (1993) · Hepatology · doi:10.1016/0270-9139(93)90505-h · Cited by 620
Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy
Black, W. C., & Welch, H. G. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304293281706 · Cited by 547
Ikeda, K., Saitoh, S., Koida, I., Arase, Y., Tsubota, A., Chayama, K., Kumada, H., & Kawanishi, M. (1993) · Hepatology · doi:10.1002/hep.1840180109 · Cited by 538
Barbara, L., Benzi, G., Gaiani, S., Fusconi, F., Zironi, G., Siringo, S., Rigamonti, A., Barbara, C., Grigioni, W., Mazziotti, A., et al. (1992) · Hepatology · doi:10.1002/hep.1840160122 · Cited by 431
Self-citationScreening for hepatocellular carcinoma
Collier, J., & Sherman, M. (1998) · Hepatology · doi:10.1002/hep.510270140 · Cited by 425
Self-citationEarly detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience
Yuen, M.-F., Cheng, C.-C., Lauder, I. J., Lam, S.-K., Ooi, C. G., & Lai, C.-L. (2000) · Hepatology · doi:10.1002/hep.510310211 · Cited by 411
Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis
Oka, H., Kurioka, N., Kim, K., Kanno, T., Kuroki, T., Mizoguchi, Y., & Kobayashi, K. (1990) · Hepatology · doi:10.1002/hep.1840120411 · Cited by 392
Sarasin, F. P., Giostra, E., & Hadengue, A. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00197-0 · Cited by 368
Gains in Life Expectancy from Medical Interventions — Standardizing Data on Outcomes
Wright, J. C., & Weinstein, M. C. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390606 · Cited by 334
Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis
Liaw, Y.-F., Tai, D.-I., Chu, C.-M., Lin, D.-Y., Sheen, I.-S., Chen, T.-J., & Pao, C. C. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90919-4 · Cited by 309
Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis
Pateron, D., Ganne, N., Trinchet, J. C., Aurousseau, M. H., Mal, F., Meicler, C., Coderc, E., Reboullet, P., & Beaugrand, M. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80468-4 · Cited by 296
Livraghi, T., Bolondi, L., Buscarini, L., Cottone, M., Mazziotti, A., Morabito, A., & Torzilli, G. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80445-5 · Cited by 278
Self-citationPrognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients
Calvet, X., Bruix, J., Ginés, P., Bru, C., Sole, M., Vilana, R., & Rodés, J. (1990) · Hepatology · doi:10.1002/hep.1840120422 · Cited by 226
Borzio, M., Bruno, S., Roncalli, M., Colloredo Mels, G., Ramella, G., Borzio, F., Leandro, G., Servida, E., & Podda, M. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90455-7 · Cited by 218
Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study
Sheu, J.-C., Sung, J.-L., Chen, D.-S., Lai, M.-Y., Wang, T.-H., Yu, J.-Y., Yang, P.-M., Chuang, C.-N., Yang, P.-C., Lee, C.-S., et al. (1985) · Cancer · doi:10.1002/1097-0142(19850801)56:3<660::aid-cncr2820560338>3.0.co;2-f · Cited by 208
Cottone, M., Turri, M., Caltagirone, M., Parisi, P., Orlando, A., Fiorentino, G., Virdone, R., Fusco, G., Grasso, R., Simonetti, R. G., et al. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80613-0 · Cited by 179
Solmi, L., Primerano, A. M., & Gandolfi, L. (1996) · PubMed · Cited by 77
Mass screening for hepatocellular carcinoma: Experience in Hokkaido, Japan
Mima, S., Sekiya, C., KANAGAWA, H., Kohyama, H., Gotoh, K., Mizuo, H., Ijiri, M., Tanabe, T., MAEDA, N., & Okuda, K. (1994) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1994.tb01256.x · Cited by 58
Follow‐up study of 582 liver cirrhosis patients for 26 years in Japan
Tanaka, R., Itoshima, T., & Nagashima, H. (1987) · Liver International · doi:10.1111/j.1600-0676.1987.tb00362.x · Cited by 45
Tremolda, F., Benevegnù, L., Drago, C., et al. (1989) · PubMed · Cited by 30
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationManagement of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Self-citationClinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Self-citationLlovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
Metadata
- Authors
- Bolondi, L., Sofia, S., Siringo, S., Gaiani, S., Casali, A., Zironi, G., Piscaglia, F., Gramantieri, L., Zanetti, M., & Sherman, M.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2001-02-01
- Volume
- 48
- Issue
- 2
- Pages
- 251-259
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2155592152
- Cited by
- 643
- References
- 34
- FWCI
- 19.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.